Intuitive Surgical, Inc. $ISRG Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 29.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,933 shares of the medical equipment provider’s stock after acquiring an additional 1,813 shares during the period. GAMMA Investing LLC’s holdings in Intuitive Surgical were worth $4,493,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Prosperity Consulting Group LLC raised its stake in Intuitive Surgical by 0.5% during the third quarter. Prosperity Consulting Group LLC now owns 4,033 shares of the medical equipment provider’s stock worth $1,804,000 after purchasing an additional 19 shares during the period. Rossmore Private Capital boosted its holdings in shares of Intuitive Surgical by 2.0% in the 3rd quarter. Rossmore Private Capital now owns 998 shares of the medical equipment provider’s stock valued at $446,000 after purchasing an additional 20 shares during the last quarter. Activest Wealth Management grew its stake in shares of Intuitive Surgical by 21.7% during the 3rd quarter. Activest Wealth Management now owns 112 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 20 shares during the period. Vertex Planning Partners LLC increased its holdings in shares of Intuitive Surgical by 2.3% during the 2nd quarter. Vertex Planning Partners LLC now owns 917 shares of the medical equipment provider’s stock worth $498,000 after buying an additional 21 shares during the last quarter. Finally, Accredited Investors Inc. increased its holdings in shares of Intuitive Surgical by 2.0% during the 3rd quarter. Accredited Investors Inc. now owns 1,060 shares of the medical equipment provider’s stock worth $474,000 after buying an additional 21 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Robert W. Baird reduced their target price on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Barclays set a $712.00 price target on Intuitive Surgical and gave the stock an “overweight” rating in a research note on Monday, January 26th. Truist Financial raised their price objective on Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Raymond James Financial lifted their price objective on Intuitive Surgical from $603.00 to $615.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Finally, UBS Group decreased their target price on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $614.95.

Insider Activity

In other news, SVP Mark Brosius sold 645 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the completion of the sale, the senior vice president directly owned 1,613 shares in the company, valued at $782,321.13. This trade represents a 28.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Myriam Curet sold 105 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $493.95, for a total value of $51,864.75. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 32,943 shares of company stock worth $17,279,568. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Up 0.5%

Shares of NASDAQ:ISRG opened at $479.93 on Friday. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $603.88. The company has a 50 day moving average of $505.00 and a two-hundred day moving average of $512.62. The company has a market capitalization of $170.44 billion, a price-to-earnings ratio of 60.83, a price-to-earnings-growth ratio of 3.68 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. The business had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.21 earnings per share. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analyst bullishness highlights ISRG as a growth play, reinforcing investor interest in the company’s long-term secular opportunity. Bull of the Day: Intuitive Surgical (ISRG)
• Positive Sentiment: Analyst note arguing ISRG can capture growth from ambulatory surgery centers as it markets lower-cost da Vinci systems — a potential multi-year revenue driver if adoption accelerates. Ambulatory Surgery Centers: A Long-Term Growth Opportunity for ISRG?
• Neutral Sentiment: A third‑party head-to-head comparison piece references ISRG alongside a smaller rival; useful for context but unlikely to move shares materially by itself. Head-To-Head Analysis: Lombard Medical & Intuitive Surgical
• Negative Sentiment: The FDA has flagged safety concerns related to Intuitive’s surgical stapler product line after reports of injuries and at least one death, urging halts and alternative device use — a major near-term regulatory and reputational risk that can slow sales, trigger recalls, or prompt increased legal exposure. FDA Flags Safety Concern Over Intuitive Surgical Stapler
• Negative Sentiment: Intuitive confirmed problems with stapler reloads and disclosed one reported death tied to the issue — amplifies regulatory scrutiny and potential product liability exposure. Intuitive warns on surgical stapler reloads with one death reported
• Negative Sentiment: Investigative coverage outlines broader operational snags (from cyber incidents to recalls), increasing short-term uncertainty around execution and compliance. From Cyber Criminals to Recalls: Inside Intuitive Surgical’s Newest Snag
• Negative Sentiment: UBS trimmed its price target on ISRG, a signal that some sell‑side investors are re‑rating the stock amid the recent safety/regulatory news — this can weigh on sentiment until clarity is provided. ISRG Price Target Lowered to $550.00 at UBS Group

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.